Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Below 200-Day Moving Average of $4.54

Minerva Neurosciences, Inc. (NASDAQ:NERV)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.54 and traded as low as $3.06. Minerva Neurosciences shares last traded at $3.14, with a volume of 5,050 shares.

Wall Street Analyst Weigh In

NERV has been the topic of several research reports. StockNews.com assumed coverage on Minerva Neurosciences in a research report on Friday. They issued a “sell” rating on the stock. HC Wainwright cut their price objective on Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating on the stock in a report on Thursday, May 2nd.

Minerva Neurosciences Trading Up 1.9 %

The business’s 50-day simple moving average is $2.83 and its 200-day simple moving average is $4.54. The company has a market capitalization of $21.95 million, a PE ratio of -0.70 and a beta of 0.15.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.07. Sell-side analysts forecast that Minerva Neurosciences, Inc. will post -1.89 EPS for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.